Skip to content

American Healthcare REIT

US · AHR #1336 by market cap Listed 2024
49.37 -1.12 -2.22%
Live - 5344 symbols - heartbeat 370s ago · 2026-10-07 20:02
After-hours 48.75 -1.26%
Market cap
11.42B
P/B
3.09
EPS
0.42
Reader sentiment Are you bullish or bearish on AHR?

Anonymous reader poll. Unscientific, not investment advice.

Valuation each multiple against its own 5-year range

P/B ratio 3.17 Expensive vs history 83rd percentile
5-year average 2.31 · #16 of 19 in REIT - Healthcare Facilities
P/E ratio 74.49 In line with history 67th percentile
5-year average -15.12 · forward 74.54 · #11 of 13 in REIT - Healthcare Facilities
P/S ratio 4.68 Expensive vs history 91st percentile
5-year average 2.74 · forward 3.83 · #10 of 19 in REIT - Healthcare Facilities

Vs. peers REIT - Healthcare Facilities

Company Market cap P/E (TTM) P/B Div yield
American Healthcare REIT (AHR) 11.42B 72.60 3.09 2.03%
Welltower (WELL) 159.37B 101.90 3.43 1.34%
Healthpeak Properties (DOC) 12.87B 53.31 1.64 6.54%
Medical Properties Trust (MPT) 1.93B -64.60 0.43 10.84%
National Healthcare Properties (NHP) 1.12B -19.48 1.06 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value52.52 Economic moatNarrow UncertaintyHigh

Trading 6.4% below Morningstar's fair value estimate.

Fair value

American Healthcare REIT Inc receives a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a minor 2% discount to our quantitative fair value estimate of $52.52 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The company's favorable dividend structure increases our estimated valuation. Dividends represent a stable form of future cash flows returned to shareholders, reducing the perceived risk of a business. For example, the firm's dividend payout ratio of 115.7% lies in the top 10% compared with peers globally. This company's generous dividend payout ratio is a boon for shareholders seeking most of their returns in the form of dividends instead of share repurchases. We believe this is a sign that shares could be cheap.

Conversely, the firm's valuation metrics are potentially concerning. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's price to cash ratio of 64.6, for example, falls in the top 10% globally. The company's available liquid assets are low relative to the stock's market value. Depending on the absolute cash balance, the company could also face a liquidity shortage if economic circumstances take a turn for the worse. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is undervalued, this outperformance had a negative impact on our valuation estimate.

Economic moat

The narrow moat rating for this company indicates investors can expect it to generate 10 years or more of excess returns on capital due to its respectable competitive advantages. Its moat is bolstered by its strong financial health, which indicates low near-term bankruptcy risk.

By Quantitative Equity Report

Quote time 2026-10-07 20:02:23 · For reference only, not investment advice and not tailored to your situation.